{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f01c6e74-de3e-44a7-9d64-4e67afed62b6",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "from collections import Counter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "e82e93e1-a46e-4ae4-87fd-3a62e9db4ffd",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(\"ctg-studies (1).json\", \"r\", encoding=\"utf-8\") as f:\n",
    "    data = json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "02105e99-b1a1-4a59-8dff-95ed9efe1034",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'protocolSection': {'identificationModule': {'nctId': 'NCT01007279',\n",
       "   'orgStudyIdInfo': {'id': 'ROMA55'},\n",
       "   'organization': {'fullName': 'University of Roma La Sapienza',\n",
       "    'class': 'OTHER'},\n",
       "   'briefTitle': 'Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)',\n",
       "   'officialTitle': 'ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis',\n",
       "   'acronym': 'ROMA'},\n",
       "  'statusModule': {'statusVerifiedDate': '2010-03',\n",
       "   'overallStatus': 'COMPLETED',\n",
       "   'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "   'startDateStruct': {'date': '2010-03'},\n",
       "   'primaryCompletionDateStruct': {'date': '2010-09', 'type': 'ACTUAL'},\n",
       "   'completionDateStruct': {'date': '2010-09', 'type': 'ACTUAL'},\n",
       "   'studyFirstSubmitDate': '2009-11-03',\n",
       "   'studyFirstSubmitQcDate': '2009-11-03',\n",
       "   'studyFirstPostDateStruct': {'date': '2009-11-04', 'type': 'ESTIMATED'},\n",
       "   'lastUpdateSubmitDate': '2010-10-25',\n",
       "   'lastUpdatePostDateStruct': {'date': '2010-10-26', 'type': 'ESTIMATED'}},\n",
       "  'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'GENNARO SARDELLA',\n",
       "    'oldOrganization': 'POLICLINICO UMBERTO I-SAPIENZA UNIVERSITY OF ROME'},\n",
       "   'leadSponsor': {'name': 'University of Roma La Sapienza',\n",
       "    'class': 'OTHER'}},\n",
       "  'oversightModule': {'oversightHasDmc': True},\n",
       "  'descriptionModule': {'briefSummary': 'An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch occlusion, intimal dissection and coronary spasm, a possible aetiology of myonecrosis after PCI might be distal embolization of atherogenic materials from plaque disruption,(2 )causing obstruction of blood flow at capillary level resulting in micro-infarction.(3,4 )Recent studies have suggested that pretreatment with Atorvastatin may be associated with a reduction in infarct size after elective PCI. (5-7 ).Actually the standard pretreatment in patients undergoing elective coronary-PCI and already treated with aspirin is copidogrel loading dose administration before procedure.(8,9 ) The investigators hypothesized that a high (40mg) loading dose of Rosuvastatin administered within 24h before the procedure may be effective in reducing the rate of periprocedural MI.Therefore, the investigators will conduct a single center,prospective randomized study to assess whether a single,high (40mg) loading (within24h)dose of Rosuvastatin is effective in preventing elevation of biomarkers of MI after elective coronary stent implantation.'},\n",
       "  'conditionsModule': {'conditions': ['Periprocedural Myocardial Necrosis'],\n",
       "   'keywords': ['Percutaneous angioplasty', 'Myocardial Infarction']},\n",
       "  'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "   'phases': ['PHASE3'],\n",
       "   'designInfo': {'allocation': 'RANDOMIZED',\n",
       "    'interventionModel': 'SINGLE_GROUP',\n",
       "    'primaryPurpose': 'TREATMENT',\n",
       "    'maskingInfo': {'masking': 'NONE'}},\n",
       "   'enrollmentInfo': {'count': 160, 'type': 'ESTIMATED'}},\n",
       "  'armsInterventionsModule': {'armGroups': [{'label': 'CLOPIDOGREL',\n",
       "     'type': 'ACTIVE_COMPARATOR',\n",
       "     'interventionNames': ['Drug: ROSUVASTATIN']},\n",
       "    {'label': 'ROSUVASTATIN',\n",
       "     'type': 'EXPERIMENTAL',\n",
       "     'interventionNames': ['Drug: ROSUVASTATIN']}],\n",
       "   'interventions': [{'type': 'DRUG',\n",
       "     'name': 'ROSUVASTATIN',\n",
       "     'description': '40 mg before procedure',\n",
       "     'armGroupLabels': ['CLOPIDOGREL', 'ROSUVASTATIN']}]},\n",
       "  'outcomesModule': {'primaryOutcomes': [{'measure': 'Myocardial enzymes arise',\n",
       "     'timeFrame': '6-12-24 hours'}],\n",
       "   'secondaryOutcomes': [{'measure': 'MACE', 'timeFrame': '1-6-9 MONTHS'}]},\n",
       "  'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients with stable angina\\n\\nExclusion Criteria:\\n\\n* Baseline myocardial enzyme rise',\n",
       "   'healthyVolunteers': False,\n",
       "   'sex': 'ALL',\n",
       "   'minimumAge': '18 Years',\n",
       "   'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "  'contactsLocationsModule': {'locations': [{'facility': 'Policlinico Umberto I',\n",
       "     'city': 'Rome',\n",
       "     'zip': '00166',\n",
       "     'country': 'Italy',\n",
       "     'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}]}},\n",
       " 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-09-11'},\n",
       "  'conditionBrowseModule': {'meshes': [{'id': 'D009203',\n",
       "     'term': 'Myocardial Infarction'}],\n",
       "   'ancestors': [{'id': 'D017202', 'term': 'Myocardial Ischemia'},\n",
       "    {'id': 'D006331', 'term': 'Heart Diseases'},\n",
       "    {'id': 'D002318', 'term': 'Cardiovascular Diseases'},\n",
       "    {'id': 'D014652', 'term': 'Vascular Diseases'},\n",
       "    {'id': 'D007238', 'term': 'Infarction'},\n",
       "    {'id': 'D007511', 'term': 'Ischemia'},\n",
       "    {'id': 'D010335', 'term': 'Pathologic Processes'},\n",
       "    {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'},\n",
       "    {'id': 'D009336', 'term': 'Necrosis'}]},\n",
       "  'interventionBrowseModule': {'meshes': [{'id': 'D000068718',\n",
       "     'term': 'Rosuvastatin Calcium'}],\n",
       "   'ancestors': [{'id': 'D013449', 'term': 'Sulfonamides'},\n",
       "    {'id': 'D000577', 'term': 'Amides'},\n",
       "    {'id': 'D009930', 'term': 'Organic Chemicals'},\n",
       "    {'id': 'D005464', 'term': 'Fluorobenzenes'},\n",
       "    {'id': 'D006845', 'term': 'Hydrocarbons, Fluorinated'},\n",
       "    {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'},\n",
       "    {'id': 'D006838', 'term': 'Hydrocarbons'},\n",
       "    {'id': 'D013450', 'term': 'Sulfones'},\n",
       "    {'id': 'D013457', 'term': 'Sulfur Compounds'},\n",
       "    {'id': 'D011743', 'term': 'Pyrimidines'},\n",
       "    {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'},\n",
       "    {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}},\n",
       " 'hasResults': False}"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "8f2d9213-6271-4c68-9b6c-3db81b3bd1a8",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'protocolSection': {'identificationModule': {'nctId': 'NCT06562582',\n",
       "   'orgStudyIdInfo': {'id': '2024-511789-35-00'},\n",
       "   'organization': {'fullName': 'Vastra Gotaland Region',\n",
       "    'class': 'OTHER_GOV'},\n",
       "   'briefTitle': 'STunning in Acute Myocardial Infarction - BAS',\n",
       "   'officialTitle': 'STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria',\n",
       "   'acronym': 'STAMI-BAS'},\n",
       "  'statusModule': {'statusVerifiedDate': '2024-08',\n",
       "   'overallStatus': 'RECRUITING',\n",
       "   'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "   'startDateStruct': {'date': '2025-01-06', 'type': 'ACTUAL'},\n",
       "   'primaryCompletionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'},\n",
       "   'completionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'},\n",
       "   'studyFirstSubmitDate': '2024-08-16',\n",
       "   'studyFirstSubmitQcDate': '2024-08-16',\n",
       "   'studyFirstPostDateStruct': {'date': '2024-08-20', 'type': 'ACTUAL'},\n",
       "   'lastUpdateSubmitDate': '2025-06-24',\n",
       "   'lastUpdatePostDateStruct': {'date': '2025-06-27', 'type': 'ACTUAL'}},\n",
       "  'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "   'leadSponsor': {'name': 'Vastra Gotaland Region', 'class': 'OTHER_GOV'}},\n",
       "  'oversightModule': {'oversightHasDmc': True,\n",
       "   'isFdaRegulatedDrug': False,\n",
       "   'isFdaRegulatedDevice': False,\n",
       "   'isUsExport': False},\n",
       "  'descriptionModule': {'briefSummary': 'The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)',\n",
       "   'detailedDescription': 'Left ventricular (LV) remodeling after ST-elevation myocardial infarction (STEMI) is associated with poor outcomes, but the mechanisms underlying adverse LV remodeling are poorly understood. It is also poorly understood how current guideline-recommended treatments affect early LV remodeling. This low interventional clinical trial will compare the effects of early versus late initiation of the three pharmacotherapies on early LV remodeling and cardiometabolic profiles.\\n\\nTrial objective:\\n\\nThe objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI).\\n\\nPrimary endpoint:\\n\\nGlobal longitudinal strain (GLS, %) at day 7±24 hours after PCI, adjusted for baseline (day 0) GLS.\\n\\nTrial design:\\n\\nThis prospective, 2x2x2 factorial, randomized, controlled, open-label, low intervention clinical trial will enroll subjects with STEMI who undergo primary percutaneous coronary intervention (PCI) within 6 hours of symptom onset.\\n\\nTrial population:\\n\\nPatients over the age of 18 with STEMI who undergo primary PCI'},\n",
       "  'conditionsModule': {'conditions': ['Myocardial Infarct'],\n",
       "   'keywords': ['ST infarction',\n",
       "    'PCI',\n",
       "    'Bisoprolol',\n",
       "    'Ramipril',\n",
       "    'Dapagliflozin',\n",
       "    'Global longitudinal strain (GLS, %)']},\n",
       "  'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "   'phases': ['PHASE4'],\n",
       "   'designInfo': {'allocation': 'RANDOMIZED',\n",
       "    'interventionModel': 'FACTORIAL',\n",
       "    'interventionModelDescription': 'This prospective, 2x2x2 factorial, randomized, controlled,',\n",
       "    'primaryPurpose': 'TREATMENT',\n",
       "    'maskingInfo': {'masking': 'NONE'}},\n",
       "   'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}},\n",
       "  'armsInterventionsModule': {'armGroups': [{'label': 'Bisoprolol',\n",
       "     'type': 'ACTIVE_COMPARATOR',\n",
       "     'description': 'Bisoprolol within 24 hours of PCI',\n",
       "     'interventionNames': ['Drug: Bisoprolol Oral Tablet']},\n",
       "    {'label': 'No Bisoprolol',\n",
       "     'type': 'NO_INTERVENTION',\n",
       "     'description': 'no beta blocker until day 7±12 hours'},\n",
       "    {'label': 'Ramipril',\n",
       "     'type': 'ACTIVE_COMPARATOR',\n",
       "     'description': 'Ramipril within 24 hours of PCI',\n",
       "     'interventionNames': ['Drug: Ramipril Oral Product']},\n",
       "    {'label': 'No Ramipril',\n",
       "     'type': 'NO_INTERVENTION',\n",
       "     'description': 'no ramipril until day 7±12 hours after PCI'},\n",
       "    {'label': 'Dapagliflozin',\n",
       "     'type': 'ACTIVE_COMPARATOR',\n",
       "     'description': 'Dapagliflozin within 24 hours versus',\n",
       "     'interventionNames': ['Drug: Dapagliflozin Oral Product']},\n",
       "    {'label': 'No Dapagliflozin',\n",
       "     'type': 'NO_INTERVENTION',\n",
       "     'description': 'no dapagliflozin treatment until day 7±12 hours after PCI'}],\n",
       "   'interventions': [{'type': 'DRUG',\n",
       "     'name': 'Bisoprolol Oral Tablet',\n",
       "     'description': 'Timing of drug intervention after PCI',\n",
       "     'armGroupLabels': ['Bisoprolol'],\n",
       "     'otherNames': ['Betablocker']},\n",
       "    {'type': 'DRUG',\n",
       "     'name': 'Ramipril Oral Product',\n",
       "     'description': 'Timing of drug intervention after PCI',\n",
       "     'armGroupLabels': ['Ramipril'],\n",
       "     'otherNames': ['ACE inhibitor']},\n",
       "    {'type': 'DRUG',\n",
       "     'name': 'Dapagliflozin Oral Product',\n",
       "     'description': 'Timing of drug intervention after PCI',\n",
       "     'armGroupLabels': ['Dapagliflozin'],\n",
       "     'otherNames': ['SGLT2 inhibitor']}]},\n",
       "  'outcomesModule': {'primaryOutcomes': [{'measure': 'Measurement of Global longitudinal strain (GLS, %)',\n",
       "     'description': 'GLS adjusted for baseline.',\n",
       "     'timeFrame': 'day 7±24 hours'}],\n",
       "   'secondaryOutcomes': [{'measure': 'Measurement of Left ventricular ejection fraction (LVEF)',\n",
       "     'description': 'LVEF adjusted for baseline',\n",
       "     'timeFrame': 'day 7±24 hours'},\n",
       "    {'measure': 'Measurement of NT-proBNP (N-terminal pro b-type natriuretic peptide )',\n",
       "     'description': 'NT-proBNP adjusted for baseline',\n",
       "     'timeFrame': 'day 7±24 hours'},\n",
       "    {'measure': 'Concentration of cardiac troponin-T',\n",
       "     'description': 'Area under the curve',\n",
       "     'timeFrame': 'Day 30'},\n",
       "    {'measure': 'Concentration of cardiac troponin-I',\n",
       "     'description': 'Area under the curve',\n",
       "     'timeFrame': 'Day 30'}],\n",
       "   'otherOutcomes': [{'measure': 'Measurement of Infarct size',\n",
       "     'description': 'MI size assessed by CMRI (sub-study)',\n",
       "     'timeFrame': 'Day 30'}]},\n",
       "  'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms)\\n2. Informed consent\\n\\nExclusion Criteria:\\n\\n1. Killip class ≥ 3\\n2. Chronic kidney disease with GFR \\\\< 25 ml/min/1.73 m2\\n3. Pre-existing non-reversible cardiac dysfunction or heart failure\\n4. Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor\\n5. Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician\\n6. Life expectancy less than one year\\n7. Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception',\n",
       "   'healthyVolunteers': False,\n",
       "   'sex': 'ALL',\n",
       "   'minimumAge': '18 Years',\n",
       "   'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "  'contactsLocationsModule': {'centralContacts': [{'name': 'Björn Redfors, Professor',\n",
       "     'role': 'CONTACT',\n",
       "     'phone': '+46 31342100',\n",
       "     'email': 'bjoern.redfors@wlab.gu.se'},\n",
       "    {'name': 'Margareta Scharin Täng, PhD',\n",
       "     'role': 'CONTACT',\n",
       "     'phone': '0736916467',\n",
       "     'email': 'margareta.scharin.tang@vgregion.se'}],\n",
       "   'locations': [{'facility': 'Sahlgrenska University Hospital',\n",
       "     'status': 'RECRUITING',\n",
       "     'city': 'Gothenburg',\n",
       "     'zip': '41345',\n",
       "     'country': 'Sweden',\n",
       "     'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}]},\n",
       "  'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED',\n",
       "   'description': 'Plan has not be decided'}},\n",
       " 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-09-11'},\n",
       "  'conditionBrowseModule': {'meshes': [{'id': 'D009203',\n",
       "     'term': 'Myocardial Infarction'}],\n",
       "   'ancestors': [{'id': 'D017202', 'term': 'Myocardial Ischemia'},\n",
       "    {'id': 'D006331', 'term': 'Heart Diseases'},\n",
       "    {'id': 'D002318', 'term': 'Cardiovascular Diseases'},\n",
       "    {'id': 'D014652', 'term': 'Vascular Diseases'},\n",
       "    {'id': 'D007238', 'term': 'Infarction'},\n",
       "    {'id': 'D007511', 'term': 'Ischemia'},\n",
       "    {'id': 'D010335', 'term': 'Pathologic Processes'},\n",
       "    {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'},\n",
       "    {'id': 'D009336', 'term': 'Necrosis'}]},\n",
       "  'interventionBrowseModule': {'meshes': [{'id': 'D017298',\n",
       "     'term': 'Bisoprolol'},\n",
       "    {'id': 'D000806', 'term': 'Angiotensin-Converting Enzyme Inhibitors'},\n",
       "    {'id': 'D000077203', 'term': 'Sodium-Glucose Transporter 2 Inhibitors'}],\n",
       "   'ancestors': [{'id': 'D050198', 'term': 'Phenoxypropanolamines'},\n",
       "    {'id': 'D011412', 'term': 'Propanolamines'},\n",
       "    {'id': 'D000605', 'term': 'Amino Alcohols'},\n",
       "    {'id': 'D000438', 'term': 'Alcohols'},\n",
       "    {'id': 'D009930', 'term': 'Organic Chemicals'},\n",
       "    {'id': 'D020005', 'term': 'Propanols'},\n",
       "    {'id': 'D000588', 'term': 'Amines'},\n",
       "    {'id': 'D011480', 'term': 'Protease Inhibitors'},\n",
       "    {'id': 'D004791', 'term': 'Enzyme Inhibitors'},\n",
       "    {'id': 'D045504',\n",
       "     'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "    {'id': 'D020228', 'term': 'Pharmacologic Actions'},\n",
       "    {'id': 'D020164', 'term': 'Chemical Actions and Uses'},\n",
       "    {'id': 'D007004', 'term': 'Hypoglycemic Agents'},\n",
       "    {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}]}},\n",
       " 'hasResults': False}"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "ebf31bf0-8cc4-402b-91b5-4f62bbd640ad",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'protocolSection': {'identificationModule': {'nctId': 'NCT03649711',\n",
       "   'orgStudyIdInfo': {'id': '227997'},\n",
       "   'secondaryIdInfos': [{'id': '1241997',\n",
       "     'type': 'OTHER',\n",
       "     'domain': 'Central Arkansas Veterans Affairs Hospital'}],\n",
       "   'organization': {'fullName': 'University of Arkansas', 'class': 'OTHER'},\n",
       "   'briefTitle': 'Chronic Kidney Disease (CKD) Platelet Study',\n",
       "   'officialTitle': 'A Mechanistic Study in Patients With Non-Dialysis Chronic Kidney Disease to Investigate Altered Platelet Response to Antiplatelet Therapy (CKD-Platelet Study)'},\n",
       "  'statusModule': {'statusVerifiedDate': '2022-08',\n",
       "   'overallStatus': 'COMPLETED',\n",
       "   'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "   'startDateStruct': {'date': '2018-11-01', 'type': 'ACTUAL'},\n",
       "   'primaryCompletionDateStruct': {'date': '2021-09-02', 'type': 'ACTUAL'},\n",
       "   'completionDateStruct': {'date': '2021-09-02', 'type': 'ACTUAL'},\n",
       "   'studyFirstSubmitDate': '2018-08-21',\n",
       "   'studyFirstSubmitQcDate': '2018-08-21',\n",
       "   'studyFirstPostDateStruct': {'date': '2018-08-28', 'type': 'ACTUAL'},\n",
       "   'resultsFirstSubmitDate': '2022-08-26',\n",
       "   'resultsFirstSubmitQcDate': '2022-12-08',\n",
       "   'resultsFirstPostDateStruct': {'date': '2022-12-29', 'type': 'ACTUAL'},\n",
       "   'lastUpdateSubmitDate': '2022-12-08',\n",
       "   'lastUpdatePostDateStruct': {'date': '2022-12-29', 'type': 'ACTUAL'}},\n",
       "  'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "   'leadSponsor': {'name': 'University of Arkansas', 'class': 'OTHER'},\n",
       "   'collaborators': [{'name': 'American Society of Nephrology',\n",
       "     'class': 'OTHER'}]},\n",
       "  'oversightModule': {'oversightHasDmc': False,\n",
       "   'isFdaRegulatedDrug': True,\n",
       "   'isFdaRegulatedDevice': False,\n",
       "   'isUsExport': False},\n",
       "  'descriptionModule': {'briefSummary': 'This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other half will be assigned to clopidogrel and aspirin in a blinded fashion. The treatment duration will be two weeks. After recruiting CKD participants the investigator will recruit controls with normal kidney function that will receive only ticagrelor and aspirin for two weeks.',\n",
       "   'detailedDescription': 'It is known that people with chronic kidney disease (CKD) are at higher risk to have heart and blood vessel problems like heart attack and stroke compared to people that do not have kidney problems. Aspirin, clopidogrel and ticagrelor prevent blood clots building up in the vessels. If a blood clot is present in one vessel, it could stop oxygen carrying blood to get to a specific organ, and that could cause problems like heart attack or stroke. There is very little knowledge about the way this group of medicines works in people with chronic kidney disease as well as it works in individuals with normal kidney function.'},\n",
       "  'conditionsModule': {'conditions': ['Chronic Kidney Diseases',\n",
       "    'Heart Attack',\n",
       "    'Stroke, Ischemic'],\n",
       "   'keywords': ['P2Y12 inhibitors',\n",
       "    'Platelet aggregation',\n",
       "    'ticagrelor',\n",
       "    'clopidogrel',\n",
       "    'chronic kidney disease']},\n",
       "  'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "   'phases': ['PHASE3'],\n",
       "   'designInfo': {'allocation': 'RANDOMIZED',\n",
       "    'interventionModel': 'PARALLEL',\n",
       "    'interventionModelDescription': 'CKD participants will be double-blind randomized in these two arms:\\n\\nArm 1 - Ticagrelor, 90 mg twice daily (one pill in the morning and one pill in the evening) + Aspirin 81 mg/day. Ticagrelor is the test treatment.\\n\\nArm 2 - Clopidogrel, 75 mg/day in the morning and a matching placebo in the evening + Aspirin 81 mg/day. Clopidogrel is the reference treatment.\\n\\nArm 3: Control with normal kidney function will be recruited after matching for age and diabetes status to the Arm 1 participants. Participants will be asked to take Ticagrelor, 90 mg twice daily (one pill in the morning and one pill in the evening) and aspirin 81 mg/day. Open label treatment.\\n\\nAll participants are required to take the oral treatment for a total of two weeks.',\n",
       "    'primaryPurpose': 'TREATMENT',\n",
       "    'maskingInfo': {'masking': 'TRIPLE',\n",
       "     'maskingDescription': 'CKD participants will be randomly assigned into one of the 2 study groups: ticagrelor (90 mg) one pill in the morning and one pill in the evening, or, clopidogrel (75 mg) one pill in the morning + placebo one pill in the evening. Placebo looks like the study drug but has no medicine in it. Neither participant nor the study personnel will know about allocation. The study drugs will look the same, except aspirin pill which will be dispensed to everyone in an open label manner.\\n\\nThere is no masking for control with normal kidney function. Participants will be asked to take open label ticagrelor, 90 mg twice daily (one pill in the morning and one pill in the evening) and aspirin 81 mg/day.',\n",
       "     'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}},\n",
       "   'enrollmentInfo': {'count': 76, 'type': 'ACTUAL'}},\n",
       "  'armsInterventionsModule': {'armGroups': [{'label': 'CKD-Ticagrelor',\n",
       "     'type': 'EXPERIMENTAL',\n",
       "     'description': 'Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d',\n",
       "     'interventionNames': ['Drug: Ticagrelor 90mg', 'Drug: Aspirin 81 mg']},\n",
       "    {'label': 'CKD-Clopidogrel',\n",
       "     'type': 'ACTIVE_COMPARATOR',\n",
       "     'description': 'Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d',\n",
       "     'interventionNames': ['Drug: Clopidogrel 75mg', 'Drug: Aspirin 81 mg']},\n",
       "    {'label': 'Control-ticagrelor',\n",
       "     'type': 'ACTIVE_COMPARATOR',\n",
       "     'description': 'Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d',\n",
       "     'interventionNames': ['Drug: Ticagrelor 90mg', 'Drug: Aspirin 81 mg']}],\n",
       "   'interventions': [{'type': 'DRUG',\n",
       "     'name': 'Ticagrelor 90mg',\n",
       "     'description': 'Ticagrelor Pill',\n",
       "     'armGroupLabels': ['CKD-Ticagrelor', 'Control-ticagrelor'],\n",
       "     'otherNames': ['Brilinta']},\n",
       "    {'type': 'DRUG',\n",
       "     'name': 'Clopidogrel 75mg',\n",
       "     'description': 'Clopidogrel Pill and a matching placebo to conceal frequency',\n",
       "     'armGroupLabels': ['CKD-Clopidogrel'],\n",
       "     'otherNames': ['Plavix']},\n",
       "    {'type': 'DRUG',\n",
       "     'name': 'Aspirin 81 mg',\n",
       "     'description': 'Aspirin Pill',\n",
       "     'armGroupLabels': ['CKD-Clopidogrel',\n",
       "      'CKD-Ticagrelor',\n",
       "      'Control-ticagrelor'],\n",
       "     'otherNames': ['baby aspirin']}]},\n",
       "  'outcomesModule': {'primaryOutcomes': [{'measure': 'ADP Induced Platelet Aggregation',\n",
       "     'description': 'We will use summary statistics to describe the distribution of the data. Post-treatment ADP-induced WBPA value in ohms (Ω) will be the primary outcome variable. We will use an analysis of covariance (ANCOVA) model to compare the treatment effects of ticagrelor vs. clopidogrel in CKD patients because this approach has higher statistical power than other methods to analyze drug effects. T',\n",
       "     'timeFrame': '2 weeks'}],\n",
       "   'secondaryOutcomes': [{'measure': 'Platelet Surface P-selectin Expression',\n",
       "     'description': 'Platelet surface P-selectin expression was measured using flow cytometry before and after treatment.',\n",
       "     'timeFrame': '2 weeks'}]},\n",
       "  'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Males and females, aged 18-91 years\\n2. Ability to understand and sign informed consent after the nature of the study has been fully explained\\n3. CKD participants: Non-dialysis CKD patients: Presence of CKD with an estimated GFR of \\\\<30 mL/min/1.73 m2 for a period of ≥3 months, as defined by the National Kidney Foundation (NKF) and determined with the CKD-EPI creatinine-based formula\\n4. Controls with normal kidney function: participants with an estimated GFR \\\\>90 mL/min/1.73 m2 as determined by the CKD-EPI creatinine-based formula and a urine albumin-to-creatinine ratio \\\\<30 mg/g as defined by the National Kidney Foundation\\n\\nExclusion Criteria:\\n\\n* No healthcare power of attorney to sign informed consent\\n* Unwillingness or inability to participate in the protocol or comply with any of its components.\\n* Subjects unable or unwilling to stop taking:\\n\\n  * Aspirin and other antithrombotic agents, like cilostazol, ranolazine, aggrenox, prasugrel, warfarin, xarelto, pradaxa, eliquis.\\n  * Glycoprotein IIb/IIIa antagonist (abciximab-ReoPro, eptifibatide-Integrilin, tirofiban-Aggrastal)\\n  * NSAIDs and PPIs\\n  * Fish oil, Vitamin E and herbal supplements\\n* Acute kidney injury superimposed on CKD\\n* Kidney transplant or any other solid organ transplant recipient\\n* End-stage kidney disease on maintenance dialysis (peritoneal or hemodialysis)\\n* Nephrotic syndrome defined as nephrotic range proteinuria, hypoalbuminemia, hyperlipidemia and generalized edema\\n* Recent hospitalization or surgery \\\\<3 months\\n* Acute coronary or cerebrovascular event in the last 12 months\\n* Blood dyscrasias, active bleeding, or bleeding diathesis\\n* Gastrointestinal bleeding in the last 6 months\\n* Recent treatment (\\\\<30 days) with a glycoprotein IIb/IIIa antagonist (Integrelin).\\n* Hematocrit \\\\<25%, white blood cell count \\\\>20,000/μL, or platelet count \\\\<50,000/μL\\n* Any active malignancy or liver disease.\\n* Pregnancy\\n* Positive urine pregnancy test in a woman of childbearing potential prior to study entry. A female of childbearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\\n\\n  * Has not undergone a hysterectomy or bilateral oophorectomy; or\\n  * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\\n* Patients must not be nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.',\n",
       "   'healthyVolunteers': True,\n",
       "   'sex': 'ALL',\n",
       "   'minimumAge': '18 Years',\n",
       "   'maximumAge': '91 Years',\n",
       "   'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "  'contactsLocationsModule': {'overallOfficials': [{'name': 'Jain Nishank, MD',\n",
       "     'affiliation': 'University of Arkansas for Medical',\n",
       "     'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "   'locations': [{'facility': 'Central Arkansas Veterans Affairs Hospital',\n",
       "     'city': 'Little Rock',\n",
       "     'state': 'Arkansas',\n",
       "     'zip': '72205',\n",
       "     'country': 'United States',\n",
       "     'geoPoint': {'lat': 34.74648, 'lon': -92.28959}},\n",
       "    {'facility': 'University of Arkansas for Medical Sciences',\n",
       "     'city': 'Little Rock',\n",
       "     'state': 'Arkansas',\n",
       "     'zip': '72205',\n",
       "     'country': 'United States',\n",
       "     'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}]},\n",
       "  'referencesModule': {'references': [{'pmid': '36682595',\n",
       "     'type': 'DERIVED',\n",
       "     'citation': 'Jain N, Corken A, Arthur JM, Ware J, Arulprakash N, Dai J, Phadnis MA, Davis O, Rahmatallah Y, Mehta JL, Hedayati SS, Smyth S. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. Vascul Pharmacol. 2023 Feb;148:107143. doi: 10.1016/j.vph.2023.107143. Epub 2023 Jan 20.'},\n",
       "    {'pmid': '35224730',\n",
       "     'type': 'DERIVED',\n",
       "     'citation': 'Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4.'}],\n",
       "   'seeAlsoLinks': [{'label': 'publication',\n",
       "     'url': 'https://kidney360.asnjournals.org/content/early/2022/10/26/KID.0005532022'}]},\n",
       "  'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "   'description': 'De-identified data for all primary and secondary outcome measures will be uploaded on clinicaltrials.gov website.',\n",
       "   'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF'],\n",
       "   'timeFrame': '2 years after study closure indefinitely'}},\n",
       " 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'Goal 48 CKD who complete visits; we ended up consenting and randomizing 50 CKD patients.\\n\\nEnrolled 26 to achieve goal. actual enrollment 50+26 = 76',\n",
       "   'recruitmentDetails': 'CKD recruitment. 50 patients signed consent and were randomized. Of those randomized, 1 received kidney transplant and 1 allergic reaction to clopidogrel and did not complete the study visits. 48 patients completed study visits.\\n\\nNon-CKD control recruitment: 26 signed consent and completed study visits.',\n",
       "   'groups': [{'id': 'FG000',\n",
       "     'title': 'Experimental: CKD-Ticagrelor',\n",
       "     'description': 'Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81mg/d'},\n",
       "    {'id': 'FG001',\n",
       "     'title': 'Arm: Active Comparator: CKD-Clopidogrel',\n",
       "     'description': 'Clopidogrel 75mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d'},\n",
       "    {'id': 'FG002',\n",
       "     'title': 'Non-CKD Control Arm: Active Comparator: Control-ticagrelor',\n",
       "     'description': 'Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d in subjects recruited without CKD'}],\n",
       "   'periods': [{'title': 'Overall Study',\n",
       "     'milestones': [{'type': 'STARTED',\n",
       "       'achievements': [{'groupId': 'FG000', 'numSubjects': '26'},\n",
       "        {'groupId': 'FG001', 'numSubjects': '24'},\n",
       "        {'groupId': 'FG002', 'numSubjects': '26'}]},\n",
       "      {'type': 'COMPLETED',\n",
       "       'achievements': [{'groupId': 'FG000', 'numSubjects': '25'},\n",
       "        {'groupId': 'FG001', 'numSubjects': '23'},\n",
       "        {'groupId': 'FG002', 'numSubjects': '26'}]},\n",
       "      {'type': 'NOT COMPLETED',\n",
       "       'achievements': [{'groupId': 'FG000', 'numSubjects': '1'},\n",
       "        {'groupId': 'FG001', 'numSubjects': '1'},\n",
       "        {'groupId': 'FG002', 'numSubjects': '0'}]}],\n",
       "     'dropWithdraws': [{'type': 'Adverse Event',\n",
       "       'reasons': [{'groupId': 'FG000', 'numSubjects': '0'},\n",
       "        {'groupId': 'FG001', 'numSubjects': '1'},\n",
       "        {'groupId': 'FG002', 'numSubjects': '0'}]},\n",
       "      {'type': 'Kidney Transplant',\n",
       "       'reasons': [{'groupId': 'FG000', 'numSubjects': '1'},\n",
       "        {'groupId': 'FG001', 'numSubjects': '0'},\n",
       "        {'groupId': 'FG002', 'numSubjects': '0'}]}]}]},\n",
       "  'baselineCharacteristicsModule': {'groups': [{'id': 'BG000',\n",
       "     'title': 'Experimental: CKD-Ticagrelor',\n",
       "     'description': 'Ticagrelor 90mg Twice daily (double blind, random assignment) + aspirin 81 mg/d'},\n",
       "    {'id': 'BG001',\n",
       "     'title': 'Active Comparator: CKD-Clopidogrel',\n",
       "     'description': 'Clpidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) aspirin 81 mg/d'},\n",
       "    {'id': 'BG002',\n",
       "     'title': 'Non-CKD Control Arm - Active Comparator: Control-ticagrelor',\n",
       "     'description': 'Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d in subjects without CKD'},\n",
       "    {'id': 'BG003',\n",
       "     'title': 'Total',\n",
       "     'description': 'Total of all reporting groups'}],\n",
       "   'denoms': [{'units': 'Participants',\n",
       "     'counts': [{'groupId': 'BG000', 'value': '25'},\n",
       "      {'groupId': 'BG001', 'value': '23'},\n",
       "      {'groupId': 'BG002', 'value': '26'},\n",
       "      {'groupId': 'BG003', 'value': '74'}]}],\n",
       "   'measures': [{'title': 'Age, Continuous',\n",
       "     'paramType': 'MEAN',\n",
       "     'dispersionType': 'STANDARD_DEVIATION',\n",
       "     'unitOfMeasure': 'years',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '55.2',\n",
       "           'spread': '11.5'},\n",
       "          {'groupId': 'BG001', 'value': '52.2', 'spread': '15.1'},\n",
       "          {'groupId': 'BG002', 'value': '48.0', 'spread': '15.2'},\n",
       "          {'groupId': 'BG003', 'value': '52.2', 'spread': '15.1'}]}]}]},\n",
       "    {'title': 'Sex: Female, Male',\n",
       "     'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "     'unitOfMeasure': 'Participants',\n",
       "     'classes': [{'categories': [{'title': 'Female',\n",
       "         'measurements': [{'groupId': 'BG000', 'value': '13'},\n",
       "          {'groupId': 'BG001', 'value': '13'},\n",
       "          {'groupId': 'BG002', 'value': '16'},\n",
       "          {'groupId': 'BG003', 'value': '42'}]},\n",
       "        {'title': 'Male',\n",
       "         'measurements': [{'groupId': 'BG000', 'value': '12'},\n",
       "          {'groupId': 'BG001', 'value': '10'},\n",
       "          {'groupId': 'BG002', 'value': '10'},\n",
       "          {'groupId': 'BG003', 'value': '32'}]}]}]},\n",
       "    {'title': 'Race/Ethnicity, Customized',\n",
       "     'paramType': 'NUMBER',\n",
       "     'unitOfMeasure': 'participants',\n",
       "     'classes': [{'title': 'African American',\n",
       "       'categories': [{'measurements': [{'groupId': 'BG000', 'value': '13'},\n",
       "          {'groupId': 'BG001', 'value': '13'},\n",
       "          {'groupId': 'BG002', 'value': '3'},\n",
       "          {'groupId': 'BG003', 'value': '29'}]}]},\n",
       "      {'title': 'Caucasian',\n",
       "       'categories': [{'measurements': [{'groupId': 'BG000', 'value': '11'},\n",
       "          {'groupId': 'BG001', 'value': '9'},\n",
       "          {'groupId': 'BG002', 'value': '21'},\n",
       "          {'groupId': 'BG003', 'value': '41'}]}]},\n",
       "      {'title': 'Hispanics',\n",
       "       'categories': [{'measurements': [{'groupId': 'BG000', 'value': '1'},\n",
       "          {'groupId': 'BG001', 'value': '0'},\n",
       "          {'groupId': 'BG002', 'value': '2'},\n",
       "          {'groupId': 'BG003', 'value': '3'}]}]},\n",
       "      {'title': 'Asian',\n",
       "       'categories': [{'measurements': [{'groupId': 'BG000', 'value': '0'},\n",
       "          {'groupId': 'BG001', 'value': '1'},\n",
       "          {'groupId': 'BG002', 'value': '0'},\n",
       "          {'groupId': 'BG003', 'value': '1'}]}]}]},\n",
       "    {'title': 'Body mass index',\n",
       "     'paramType': 'MEAN',\n",
       "     'dispersionType': 'STANDARD_DEVIATION',\n",
       "     'unitOfMeasure': 'kg/m^2',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '34.5',\n",
       "           'spread': '8.6'},\n",
       "          {'groupId': 'BG001', 'value': '32.5', 'spread': '9.1'},\n",
       "          {'groupId': 'BG002', 'value': '31.2', 'spread': '7.0'},\n",
       "          {'groupId': 'BG003', 'value': '33.5', 'spread': '8.8'}]}]}]},\n",
       "    {'title': 'Diabetes mellitus, n (%)',\n",
       "     'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "     'unitOfMeasure': 'Participants',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '17'},\n",
       "          {'groupId': 'BG001', 'value': '14'},\n",
       "          {'groupId': 'BG002', 'value': '0'},\n",
       "          {'groupId': 'BG003', 'value': '31'}]}]}]},\n",
       "    {'title': 'Statin use, n (%)',\n",
       "     'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "     'unitOfMeasure': 'Participants',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '15'},\n",
       "          {'groupId': 'BG001', 'value': '14'},\n",
       "          {'groupId': 'BG002', 'value': '4'},\n",
       "          {'groupId': 'BG003', 'value': '33'}]}]}]},\n",
       "    {'title': 'Baseline use of aspirin, n (%)',\n",
       "     'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "     'unitOfMeasure': 'Participants',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '10'},\n",
       "          {'groupId': 'BG001', 'value': '7'},\n",
       "          {'groupId': 'BG002', 'value': '3'},\n",
       "          {'groupId': 'BG003', 'value': '20'}]}]}]},\n",
       "    {'title': 'Serum creatinine',\n",
       "     'paramType': 'MEAN',\n",
       "     'dispersionType': 'STANDARD_DEVIATION',\n",
       "     'unitOfMeasure': 'mg/dl',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '4.2',\n",
       "           'spread': '1.9'},\n",
       "          {'groupId': 'BG001', 'value': '4.3', 'spread': '1.8'},\n",
       "          {'groupId': 'BG002', 'value': '0.9', 'spread': '0.1'},\n",
       "          {'groupId': 'BG003', 'value': '4.2', 'spread': '1.9'}]}]}]},\n",
       "    {'title': 'eGFR',\n",
       "     'paramType': 'MEAN',\n",
       "     'dispersionType': 'STANDARD_DEVIATION',\n",
       "     'unitOfMeasure': 'mL/min/1.73 m^2',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '16.7',\n",
       "           'spread': '6.5'},\n",
       "          {'groupId': 'BG001', 'value': '16.4', 'spread': '5.7'},\n",
       "          {'groupId': 'BG002', 'value': '89.6', 'spread': '13.2'},\n",
       "          {'groupId': 'BG003', 'value': '16.5', 'spread': '6.0'}]}]}]},\n",
       "    {'title': 'Urine albumin-to-creatinine ratio',\n",
       "     'paramType': 'MEDIAN',\n",
       "     'dispersionType': 'INTER_QUARTILE_RANGE',\n",
       "     'unitOfMeasure': 'mg/g of creatinine',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '1,039.0',\n",
       "           'lowerLimit': '715.6',\n",
       "           'upperLimit': '2,382.5'},\n",
       "          {'groupId': 'BG001',\n",
       "           'value': '2,400.0',\n",
       "           'lowerLimit': '519.7',\n",
       "           'upperLimit': '4,243.0'},\n",
       "          {'groupId': 'BG002',\n",
       "           'value': '0',\n",
       "           'lowerLimit': '0',\n",
       "           'upperLimit': '0'},\n",
       "          {'groupId': 'BG003',\n",
       "           'value': '1,229.4',\n",
       "           'lowerLimit': '638.0',\n",
       "           'upperLimit': '3,329.0'}]}]}]},\n",
       "    {'title': 'Hemoglobin',\n",
       "     'paramType': 'MEAN',\n",
       "     'dispersionType': 'STANDARD_DEVIATION',\n",
       "     'unitOfMeasure': 'g/dl',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '11.1',\n",
       "           'spread': '1.8'},\n",
       "          {'groupId': 'BG001', 'value': '11.1', 'spread': '1.9'},\n",
       "          {'groupId': 'BG002', 'value': '13.5', 'spread': '1.3'},\n",
       "          {'groupId': 'BG003', 'value': '13.5', 'spread': '1.3'}]}]}]},\n",
       "    {'title': 'White blood cell count',\n",
       "     'paramType': 'MEAN',\n",
       "     'dispersionType': 'STANDARD_DEVIATION',\n",
       "     'unitOfMeasure': '1000 cells per µL',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '7.7',\n",
       "           'spread': '2.4'},\n",
       "          {'groupId': 'BG001', 'value': '7.5', 'spread': '2.4'},\n",
       "          {'groupId': 'BG002', 'value': '6.2', 'spread': '1.6'},\n",
       "          {'groupId': 'BG003', 'value': '7.6', 'spread': '2.4'}]}]}]},\n",
       "    {'title': 'Platelet count',\n",
       "     'paramType': 'MEDIAN',\n",
       "     'dispersionType': 'STANDARD_DEVIATION',\n",
       "     'unitOfMeasure': '1000 cells per µL',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '243.07',\n",
       "           'spread': '71.1'},\n",
       "          {'groupId': 'BG001', 'value': '229.9', 'spread': '49.7'},\n",
       "          {'groupId': 'BG002', 'value': '266.5', 'spread': '57.9'},\n",
       "          {'groupId': 'BG003', 'value': '236.7', 'spread': '61.5'}]}]}]},\n",
       "    {'title': 'Percent of Hemoglobin A1c',\n",
       "     'paramType': 'MEAN',\n",
       "     'dispersionType': 'STANDARD_DEVIATION',\n",
       "     'unitOfMeasure': 'percentage of hemoglobin',\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "           'value': '6.9',\n",
       "           'spread': '1.6'},\n",
       "          {'groupId': 'BG001', 'value': '7.0', 'spread': '1.9'},\n",
       "          {'groupId': 'BG002', 'value': '5.3', 'spread': '0.4'},\n",
       "          {'groupId': 'BG003', 'value': '6.9', 'spread': '1.6'}]}]}]}]},\n",
       "  'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY',\n",
       "     'title': 'ADP Induced Platelet Aggregation',\n",
       "     'description': 'We will use summary statistics to describe the distribution of the data. Post-treatment ADP-induced WBPA value in ohms (Ω) will be the primary outcome variable. We will use an analysis of covariance (ANCOVA) model to compare the treatment effects of ticagrelor vs. clopidogrel in CKD patients because this approach has higher statistical power than other methods to analyze drug effects. T',\n",
       "     'populationDescription': 'CKD groups were analyzed between randomized arms using ANCOVA. CK-ticagrelor arm was compared to control ticagrelor arm using Wilcoxon rank sum test.',\n",
       "     'reportingStatus': 'POSTED',\n",
       "     'paramType': 'MEDIAN',\n",
       "     'dispersionType': 'Inter-Quartile Range',\n",
       "     'unitOfMeasure': 'ohms',\n",
       "     'timeFrame': '2 weeks',\n",
       "     'groups': [{'id': 'OG000',\n",
       "       'title': 'CKD-Ticagrelor',\n",
       "       'description': 'Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d\\n\\nTicagrelor 90mg: Ticagrelor Pill\\n\\nAspirin 81 mg: Aspirin Pill'},\n",
       "      {'id': 'OG001',\n",
       "       'title': 'CKD-Clopidogrel',\n",
       "       'description': 'Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d\\n\\nClopidogrel 75mg: Clopidogrel Pill and a matching placebo to conceal frequency\\n\\nAspirin 81 mg: Aspirin Pill'},\n",
       "      {'id': 'OG002',\n",
       "       'title': 'Control-ticagrelor',\n",
       "       'description': 'Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d\\n\\nTicagrelor 90mg: Ticagrelor Pill\\n\\nAspirin 81 mg: Aspirin Pill'}],\n",
       "     'denoms': [{'units': 'Participants',\n",
       "       'counts': [{'groupId': 'OG000', 'value': '25'},\n",
       "        {'groupId': 'OG001', 'value': '23'},\n",
       "        {'groupId': 'OG002', 'value': '26'}]}],\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "           'value': '0',\n",
       "           'lowerLimit': '0',\n",
       "           'upperLimit': '2'},\n",
       "          {'groupId': 'OG001',\n",
       "           'value': '6',\n",
       "           'lowerLimit': '1',\n",
       "           'upperLimit': '10.5'},\n",
       "          {'groupId': 'OG002',\n",
       "           'value': '1',\n",
       "           'lowerLimit': '0',\n",
       "           'upperLimit': '3'}]}]}],\n",
       "     'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "       'nonInferiorityType': 'OTHER',\n",
       "       'nonInferiorityComment': 'Post treatment values were compared using ANCOVA',\n",
       "       'pValue': '0.002',\n",
       "       'statisticalMethod': 'ANCOVA'},\n",
       "      {'groupIds': ['OG000', 'OG002'],\n",
       "       'groupDescription': 'mean changes in values were compared by Wilcoxon rank sum test adjusted for multiple comparisons (Bonferonni method) between CKD-ticagrelor arm, and the non-CKD controls',\n",
       "       'nonInferiorityType': 'OTHER',\n",
       "       'pValue': '0.18',\n",
       "       'statisticalMethod': 'Wilcoxon (Mann-Whitney)'}]},\n",
       "    {'type': 'SECONDARY',\n",
       "     'title': 'Platelet Surface P-selectin Expression',\n",
       "     'description': 'Platelet surface P-selectin expression was measured using flow cytometry before and after treatment.',\n",
       "     'populationDescription': 'CKD groups were analyzed between randomized arms using ANCOVA. CK-ticagrelor arm was compared to control ticagrelor arm using Wilcoxon rank sum test.',\n",
       "     'reportingStatus': 'POSTED',\n",
       "     'paramType': 'MEDIAN',\n",
       "     'dispersionType': 'Inter-Quartile Range',\n",
       "     'unitOfMeasure': 'Fluorescence intensity',\n",
       "     'timeFrame': '2 weeks',\n",
       "     'groups': [{'id': 'OG000',\n",
       "       'title': 'CKD-Ticagrelor',\n",
       "       'description': 'Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d\\n\\nTicagrelor 90mg: Ticagrelor Pill\\n\\nAspirin 81 mg: Aspirin Pill'},\n",
       "      {'id': 'OG001',\n",
       "       'title': 'CKD-Clopidogrel',\n",
       "       'description': 'Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d\\n\\nClopidogrel 75mg: Clopidogrel Pill and a matching placebo to conceal frequency\\n\\nAspirin 81 mg: Aspirin Pill'},\n",
       "      {'id': 'OG002',\n",
       "       'title': 'Control-ticagrelor',\n",
       "       'description': 'Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d\\n\\nTicagrelor 90mg: Ticagrelor Pill\\n\\nAspirin 81 mg: Aspirin Pill'}],\n",
       "     'denoms': [{'units': 'Participants',\n",
       "       'counts': [{'groupId': 'OG000', 'value': '25'},\n",
       "        {'groupId': 'OG001', 'value': '23'},\n",
       "        {'groupId': 'OG002', 'value': '26'}]}],\n",
       "     'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "           'value': '1002.5',\n",
       "           'lowerLimit': '758.5',\n",
       "           'upperLimit': '1149.5'},\n",
       "          {'groupId': 'OG001',\n",
       "           'value': '1037.5',\n",
       "           'lowerLimit': '848.5',\n",
       "           'upperLimit': '1262.75'},\n",
       "          {'groupId': 'OG002',\n",
       "           'value': '1052',\n",
       "           'lowerLimit': '810',\n",
       "           'upperLimit': '1279'}]}]}],\n",
       "     'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "       'groupDescription': 'CKD groups randomized were compared for post treatment values.',\n",
       "       'nonInferiorityType': 'OTHER',\n",
       "       'pValue': '0.22',\n",
       "       'statisticalMethod': 'ANCOVA'}]}]},\n",
       "  'adverseEventsModule': {'frequencyThreshold': '5',\n",
       "   'timeFrame': 'Adverse events reported during the 2 weeks of treatment from baseline visit to the final visit',\n",
       "   'eventGroups': [{'id': 'EG000',\n",
       "     'title': 'Experimental: CKD-Ticagrelor',\n",
       "     'description': 'Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81mg/d',\n",
       "     'deathsNumAffected': 0,\n",
       "     'deathsNumAtRisk': 25,\n",
       "     'seriousNumAffected': 1,\n",
       "     'seriousNumAtRisk': 25,\n",
       "     'otherNumAffected': 14,\n",
       "     'otherNumAtRisk': 25},\n",
       "    {'id': 'EG001',\n",
       "     'title': 'Arm: Active Comparator: CKD-Clopidogrel',\n",
       "     'description': 'Clopidogrel 75mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d',\n",
       "     'deathsNumAffected': 0,\n",
       "     'deathsNumAtRisk': 23,\n",
       "     'seriousNumAffected': 0,\n",
       "     'seriousNumAtRisk': 23,\n",
       "     'otherNumAffected': 11,\n",
       "     'otherNumAtRisk': 23},\n",
       "    {'id': 'EG002',\n",
       "     'title': 'Arm: Active Comparator: Control-ticagrelor',\n",
       "     'description': 'Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d',\n",
       "     'deathsNumAffected': 0,\n",
       "     'deathsNumAtRisk': 26,\n",
       "     'seriousNumAffected': 0,\n",
       "     'seriousNumAtRisk': 26,\n",
       "     'otherNumAffected': 13,\n",
       "     'otherNumAtRisk': 26}],\n",
       "   'seriousEvents': [{'term': 'Hospitalization',\n",
       "     'organSystem': 'Blood and lymphatic system disorders',\n",
       "     'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "     'notes': 'for anemia requiring blood transfusion, possibly arising from worsening anemia of chronic kidney disease, no evidence of bleeding',\n",
       "     'stats': [{'groupId': 'EG000',\n",
       "       'numEvents': 1,\n",
       "       'numAffected': 1,\n",
       "       'numAtRisk': 25},\n",
       "      {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 23},\n",
       "      {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 26}]}],\n",
       "   'otherEvents': [{'term': 'Bruise',\n",
       "     'organSystem': 'Injury, poisoning and procedural complications',\n",
       "     'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "     'stats': [{'groupId': 'EG000', 'numAffected': 12, 'numAtRisk': 25},\n",
       "      {'groupId': 'EG001', 'numAffected': 9, 'numAtRisk': 23},\n",
       "      {'groupId': 'EG002', 'numAffected': 13, 'numAtRisk': 26}]},\n",
       "    {'term': 'Dyspnea',\n",
       "     'organSystem': 'Cardiac disorders',\n",
       "     'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "     'stats': [{'groupId': 'EG000', 'numAffected': 5, 'numAtRisk': 25},\n",
       "      {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 23},\n",
       "      {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 26}]},\n",
       "    {'term': 'Fatigue',\n",
       "     'organSystem': 'General disorders',\n",
       "     'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "     'stats': [{'groupId': 'EG000', 'numAffected': 2, 'numAtRisk': 25},\n",
       "      {'groupId': 'EG001', 'numAffected': 4, 'numAtRisk': 23},\n",
       "      {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 26}]},\n",
       "    {'term': 'Acidity',\n",
       "     'organSystem': 'Gastrointestinal disorders',\n",
       "     'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "     'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 25},\n",
       "      {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 23},\n",
       "      {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 26}]}]},\n",
       "  'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': True,\n",
       "    'restrictiveAgreement': False},\n",
       "   'pointOfContact': {'title': 'Dr. Nishank Jain, Associate Professor of Medicine',\n",
       "    'organization': 'University of Arkansas for Medical Sciences',\n",
       "    'email': 'njain2@uams.edu',\n",
       "    'phone': '5016865295'}}},\n",
       " 'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP',\n",
       "     'hasProtocol': True,\n",
       "     'hasSap': True,\n",
       "     'hasIcf': False,\n",
       "     'label': 'Study Protocol and Statistical Analysis Plan',\n",
       "     'date': '2021-02-22',\n",
       "     'uploadDate': '2022-10-03T14:05',\n",
       "     'filename': 'Prot_SAP_002.pdf',\n",
       "     'size': 855344},\n",
       "    {'typeAbbrev': 'ICF',\n",
       "     'hasProtocol': False,\n",
       "     'hasSap': False,\n",
       "     'hasIcf': True,\n",
       "     'label': 'Informed Consent Form',\n",
       "     'date': '2020-07-23',\n",
       "     'uploadDate': '2022-10-03T14:07',\n",
       "     'filename': 'ICF_003.pdf',\n",
       "     'size': 469326}]}},\n",
       " 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-09-11',\n",
       "   'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2022-09-26',\n",
       "      'type': 'ACTUAL'}}}},\n",
       "  'conditionBrowseModule': {'meshes': [{'id': 'D051436',\n",
       "     'term': 'Renal Insufficiency, Chronic'},\n",
       "    {'id': 'D009203', 'term': 'Myocardial Infarction'},\n",
       "    {'id': 'D000083242', 'term': 'Ischemic Stroke'}],\n",
       "   'ancestors': [{'id': 'D051437', 'term': 'Renal Insufficiency'},\n",
       "    {'id': 'D007674', 'term': 'Kidney Diseases'},\n",
       "    {'id': 'D014570', 'term': 'Urologic Diseases'},\n",
       "    {'id': 'D052776', 'term': 'Female Urogenital Diseases'},\n",
       "    {'id': 'D005261',\n",
       "     'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "    {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "    {'id': 'D052801', 'term': 'Male Urogenital Diseases'},\n",
       "    {'id': 'D002908', 'term': 'Chronic Disease'},\n",
       "    {'id': 'D020969', 'term': 'Disease Attributes'},\n",
       "    {'id': 'D010335', 'term': 'Pathologic Processes'},\n",
       "    {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'},\n",
       "    {'id': 'D017202', 'term': 'Myocardial Ischemia'},\n",
       "    {'id': 'D006331', 'term': 'Heart Diseases'},\n",
       "    {'id': 'D002318', 'term': 'Cardiovascular Diseases'},\n",
       "    {'id': 'D014652', 'term': 'Vascular Diseases'},\n",
       "    {'id': 'D007238', 'term': 'Infarction'},\n",
       "    {'id': 'D007511', 'term': 'Ischemia'},\n",
       "    {'id': 'D009336', 'term': 'Necrosis'},\n",
       "    {'id': 'D020521', 'term': 'Stroke'},\n",
       "    {'id': 'D002561', 'term': 'Cerebrovascular Disorders'},\n",
       "    {'id': 'D001927', 'term': 'Brain Diseases'},\n",
       "    {'id': 'D002493', 'term': 'Central Nervous System Diseases'},\n",
       "    {'id': 'D009422', 'term': 'Nervous System Diseases'}]},\n",
       "  'interventionBrowseModule': {'meshes': [{'id': 'D000077486',\n",
       "     'term': 'Ticagrelor'},\n",
       "    {'id': 'D000077144', 'term': 'Clopidogrel'},\n",
       "    {'id': 'D001241', 'term': 'Aspirin'}],\n",
       "   'ancestors': [{'id': 'D000241', 'term': 'Adenosine'},\n",
       "    {'id': 'D011684', 'term': 'Purine Nucleosides'},\n",
       "    {'id': 'D011687', 'term': 'Purines'},\n",
       "    {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'},\n",
       "    {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'},\n",
       "    {'id': 'D006571', 'term': 'Heterocyclic Compounds'},\n",
       "    {'id': 'D009705', 'term': 'Nucleosides'},\n",
       "    {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'},\n",
       "    {'id': 'D012263', 'term': 'Ribonucleosides'},\n",
       "    {'id': 'D013988', 'term': 'Ticlopidine'},\n",
       "    {'id': 'D058924', 'term': 'Thienopyridines'},\n",
       "    {'id': 'D013876', 'term': 'Thiophenes'},\n",
       "    {'id': 'D013457', 'term': 'Sulfur Compounds'},\n",
       "    {'id': 'D009930', 'term': 'Organic Chemicals'},\n",
       "    {'id': 'D011725', 'term': 'Pyridines'},\n",
       "    {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'},\n",
       "    {'id': 'D012459', 'term': 'Salicylates'},\n",
       "    {'id': 'D062385', 'term': 'Hydroxybenzoates'},\n",
       "    {'id': 'D010636', 'term': 'Phenols'},\n",
       "    {'id': 'D001555', 'term': 'Benzene Derivatives'},\n",
       "    {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'},\n",
       "    {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'},\n",
       "    {'id': 'D006838', 'term': 'Hydrocarbons'}]}},\n",
       " 'hasResults': True}"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data[100]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "45162ab0-60f5-442f-b794-d22e3bb41c5a",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
